<p>WBH Advisory Inc. 在最近向證券交易委員會提交的 13F 表格中表示，在第一季度將其在禮來的股份減少了 6.4%。該機構投資者在此期間出售了 574 股後，持有該公司 8,400 股股票。截至其最近向證券交易委員會提交的文件，WBH Advisory Inc. 在禮來的持股價值為 6,938,000 美元。</p>
<p>獲取 <strong>禮來</strong> 的提醒：</p>
<ul>
<li>特朗普 GLP-1 試點計劃可能推動諾和諾德和禮來的增長</li>
</ul>
<p>其他一些對沖基金和機構投資者最近也對該公司的持倉進行了調整。Garner Asset Management Corp 在第四季度將其在禮來的持倉提高了 2.3%。Garner Asset Management Corp 目前持有 532 股該公司的股票，價值 411,000 美元，此前在上個季度增持了 12 股。Tobias Financial Advisors Inc. 在第四季度將其在禮來的股份提高了 4.1%。Tobias Financial Advisors Inc. 目前持有 307 股該公司的股票，價值 237,000 美元，此前在上個季度增持了 12 股。Redwood Investments LLC 在第四季度將其在禮來的持股提高了 0.5%。Redwood Investments LLC 目前持有 2,209 股該公司的股票，價值 1,705,000 美元，此前在上個季度增持了 12 股。Hobbs Wealth Management LLC 在第一季度將其在禮來的持倉提高了 0.8%。Hobbs Wealth Management LLC 目前持有 1,459 股該公司的股票，價值 1,205,000 美元，此前在此期間增持了 12 股。最後，Hixon Zuercher LLC 在第一季度將其在禮來的持股提高了 0.7%。Hixon Zuercher LLC 目前持有 1,789 股該公司的股票，價值 1,477,000 美元，此前在上個季度增持了 12 股。82.53% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>禮來股票下跌 14.2%</h2>
<p>禮來股票週五開盤價為 640.17 美元。該公司的 50 日移動平均價格為 776.36 美元，200 日移動平均價格為 799.60 美元。禮來公司的 12 個月低點為 633.20 美元，12 個月高點為 972.53 美元。該公司的流動比率為 1.37，速動比率為 1.06，債務與股本比率為 2.18。該股票的市值為 6067.1 億美元，市盈率為 52.09，市盈增長比率為 1.06，貝塔值為 0.44。</p>
<ul>
<li>諾和諾德股票下跌——但是否終於觸底？</li>
</ul>
<p>禮來公司（NYSE:LLY - 獲取免費報告）最近在 8 月 7 日星期四公佈了季度財報。該公司報告每股收益（EPS）為 6.31 美元，超出市場共識預期的 5.59 美元，超出 0.72 美元。該公司在本季度的收入為 155.6 億美元，而分析師預期為 144.0 億美元。禮來公司的淨利潤率為 22.67%，股本回報率為 85.51%。該公司的收入同比增長 37.6%。在去年同期，該公司每股收益為 3.92 美元。整體來看，股票研究分析師預計禮來公司在當前財年將發佈 23.48 美元的每股收益。</p>
<h2>禮來公司分紅公告</h2>
<p>該公司還最近宣佈了一項季度分紅，將於 9 月 10 日星期三支付。8 月 15 日星期五的登記投資者將獲得每股 1.50 美元的分紅。除息日為 8 月 15 日星期五。這代表着每年 6.00 美元的分紅和 0.9% 的分紅收益率。禮來公司的分紅支付比率目前為 48.82%。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>醫療保健股票估值觸底，3 個名字有望反彈</li>
</ul>
<p>禮來股票已成為幾份研究報告的主題。富國銀行在 5 月 1 日星期四的研究報告中重申了對禮來股票的 “增持” 評級。摩根士丹利在 7 月 10 日星期四的研究報告中重申了 “增持” 評級，並將禮來股票的目標價從 1,133.00 美元上調至 1,135.00 美元。Leerink Partners 在一份報告中重申了 “市場表現” 評級，並將禮來股票的目標價定為 715.00 美元。華爾街 Zen 在 7 月 26 日星期六的報告中將禮來公司從 “持有” 評級上調至 “買入” 評級。最後，Guggenheim 將禮來公司的目標價從 936.00 美元上調至 942.00 美元，並在 7 月 11 日星期五的報告中給予該股票 “買入” 評級。一位分析師對該股票給予了賣出評級，四位給予了持有評級，十七位給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 999.50 美元。</p>
<p><strong>獲取我們關於禮來的最新報告</strong></p>
<h2>關於禮來公司</h2>
<p>（免費報告）</p>
<p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過禮來公司</li>
<li>Roth IRA 計算器：計算您的潛在回報</li>
<li>為什麼單片電源的收益和指引引發了市場反彈</li>
<li>3 只家居改善股票可以升級您的投資組合</li>
<li>AppLovin 第二季度業績不佳讓市場緊張，但華爾街加倍下注</li>
<li>如何開始投資房地產</li>
<li>微軟股票上漲，分析師提高目標價</li>
</ul>
<p><strong>想知道其他對 LLY 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Eli Lilly and Company (NYSE:LLY - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Eli Lilly and Company 嗎？</h2>
<p>在考慮 Eli Lilly and Company 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Eli Lilly and Company 並不在名單上。</p>
<p>雖然 Eli Lilly and Company 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

禮來

<p>WBH Advisory Inc. 在第一季度減少了對禮來的持股比例，降幅為 6.4%，目前持有 8,400 股，價值約為 694 萬美元。其他機構投資者也調整了他們的持倉，其中 82.53% 的股票由這些實體持有。禮來的股票價格下跌了 14.2%，當前價格為 640.17 美元。該公司報告了強勁的收益，每股收益為 6.31 美元，超出預期，並宣佈每股季度分紅為 1.50 美元</p>

<p>WBH Advisory Inc. trimmed its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,400 shares of the company's stock after selling 574 shares during the period. WBH Advisory Inc.'s holdings in Eli Lilly and Company were worth $6,938,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>WBH Advisory Inc. 在最近向證券交易委員會提交的 13F 表格中表示，在第一季度將其在禮來的股份減少了 6.4%。該機構投資者在此期間出售了 574 股後，持有該公司 8,400 股股票。截至其最近向證券交易委員會提交的文件，WBH Advisory Inc. 在禮來的持股價值為 6,938,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>禮來</strong> 的提醒：</p>
</div><ul>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
</ul>
<div class="lb-trans"><ul>
<li>特朗普 GLP-1 試點計劃可能推動諾和諾德和禮來的增長</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Garner Asset Management Corp lifted its position in Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after acquiring an additional 12 shares during the last quarter. Tobias Financial Advisors Inc. boosted its position in shares of Eli Lilly and Company by 4.1% during the 4th quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company's stock valued at $237,000 after acquiring an additional 12 shares in the last quarter. Redwood Investments LLC boosted its holdings in Eli Lilly and Company by 0.5% during the fourth quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock valued at $1,705,000 after purchasing an additional 12 shares in the last quarter. Hobbs Wealth Management LLC grew its position in Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after acquiring an additional 12 shares during the period. Finally, Hixon Zuercher LLC grew its holdings in shares of Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after purchasing an additional 12 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者最近也對該公司的持倉進行了調整。Garner Asset Management Corp 在第四季度將其在禮來的持倉提高了 2.3%。Garner Asset Management Corp 目前持有 532 股該公司的股票，價值 411,000 美元，此前在上個季度增持了 12 股。Tobias Financial Advisors Inc. 在第四季度將其在禮來的股份提高了 4.1%。Tobias Financial Advisors Inc. 目前持有 307 股該公司的股票，價值 237,000 美元，此前在上個季度增持了 12 股。Redwood Investments LLC 在第四季度將其在禮來的持股提高了 0.5%。Redwood Investments LLC 目前持有 2,209 股該公司的股票，價值 1,705,000 美元，此前在上個季度增持了 12 股。Hobbs Wealth Management LLC 在第一季度將其在禮來的持倉提高了 0.8%。Hobbs Wealth Management LLC 目前持有 1,459 股該公司的股票，價值 1,205,000 美元，此前在此期間增持了 12 股。最後，Hixon Zuercher LLC 在第一季度將其在禮來的持股提高了 0.7%。Hixon Zuercher LLC 目前持有 1,789 股該公司的股票，價值 1,477,000 美元，此前在上個季度增持了 12 股。82.53% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Eli Lilly and Company Stock Down 14.2%</h2>
<div class="lb-trans"><h2>禮來股票下跌 14.2%</h2>
</div><p>LLY stock opened at $640.17 on Friday. The firm has a 50-day moving average price of $776.36 and a 200-day moving average price of $799.60. Eli Lilly and Company has a 12 month low of $633.20 and a 12 month high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $606.71 billion, a P/E ratio of 52.09, a price-to-earnings-growth ratio of 1.06 and a beta of 0.44.</p>
<div class="lb-trans"><p>禮來股票週五開盤價為 640.17 美元。該公司的 50 日移動平均價格為 776.36 美元，200 日移動平均價格為 799.60 美元。禮來公司的 12 個月低點為 633.20 美元，12 個月高點為 972.53 美元。該公司的流動比率為 1.37，速動比率為 1.06，債務與股本比率為 2.18。該股票的市值為 6067.1 億美元，市盈率為 52.09，市盈增長比率為 1.06，貝塔值為 0.44。</p>
</div><ul>
<li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li>
</ul>
<div class="lb-trans"><ul>
<li>諾和諾德股票下跌——但是否終於觸底？</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company's revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the company posted $3.92 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>禮來公司（NYSE:LLY - 獲取免費報告）最近在 8 月 7 日星期四公佈了季度財報。該公司報告每股收益（EPS）為 6.31 美元，超出市場共識預期的 5.59 美元，超出 0.72 美元。該公司在本季度的收入為 155.6 億美元，而分析師預期為 144.0 億美元。禮來公司的淨利潤率為 22.67%，股本回報率為 85.51%。該公司的收入同比增長 37.6%。在去年同期，該公司每股收益為 3.92 美元。整體來看，股票研究分析師預計禮來公司在當前財年將發佈 23.48 美元的每股收益。</p>
</div><h2>Eli Lilly and Company Dividend Announcement</h2>
<div class="lb-trans"><h2>禮來公司分紅公告</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.9%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.</p>
<div class="lb-trans"><p>該公司還最近宣佈了一項季度分紅，將於 9 月 10 日星期三支付。8 月 15 日星期五的登記投資者將獲得每股 1.50 美元的分紅。除息日為 8 月 15 日星期五。這代表着每年 6.00 美元的分紅和 0.9% 的分紅收益率。禮來公司的分紅支付比率目前為 48.82%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>醫療保健股票估值觸底，3 個名字有望反彈</li>
</ul>
</div><p>LLY has been the topic of several research reports. Wells Fargo &amp; Company reiterated an &#34;overweight&#34; rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Morgan Stanley restated an &#34;overweight&#34; rating and issued a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Leerink Partners restated a &#34;market perform&#34; rating and set a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday. Wall Street Zen upgraded Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, July 26th. Finally, Guggenheim increased their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 11th. One analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $999.50.</p>
<div class="lb-trans"><p>禮來股票已成為幾份研究報告的主題。富國銀行在 5 月 1 日星期四的研究報告中重申了對禮來股票的 “增持” 評級。摩根士丹利在 7 月 10 日星期四的研究報告中重申了 “增持” 評級，並將禮來股票的目標價從 1,133.00 美元上調至 1,135.00 美元。Leerink Partners 在一份報告中重申了 “市場表現” 評級，並將禮來股票的目標價定為 715.00 美元。華爾街 Zen 在 7 月 26 日星期六的報告中將禮來公司從 “持有” 評級上調至 “買入” 評級。最後，Guggenheim 將禮來公司的目標價從 936.00 美元上調至 942.00 美元，並在 7 月 11 日星期五的報告中給予該股票 “買入” 評級。一位分析師對該股票給予了賣出評級，四位給予了持有評級，十七位給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 999.50 美元。</p>
</div><p><strong>Get Our Latest Report on LLY</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於禮來的最新報告</strong></p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>關於禮來公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>Why Monolithic Power's Earnings and Guidance Ignited a Rally</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down</li>
<li>How to Start Investing in Real Estate</li>
<li>Microsoft Stock Gains as Analysts Boost Price Targets</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過禮來公司</li>
<li>Roth IRA 計算器：計算您的潛在回報</li>
<li>為什麼單片電源的收益和指引引發了市場反彈</li>
<li>3 只家居改善股票可以升級您的投資組合</li>
<li>AppLovin 第二季度業績不佳讓市場緊張，但華爾街加倍下注</li>
<li>如何開始投資房地產</li>
<li>微軟股票上漲，分析師提高目標價</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對 LLY 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Eli Lilly and Company (NYSE:LLY - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Eli Lilly and Company 嗎？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Eli Lilly and Company 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Eli Lilly and Company 並不在名單上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Eli Lilly and Company 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

WBH Advisory Inc. 在禮來公司（NYSE:LLY）中持有價值 694 萬美元的股份